Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications (link to LDN patents), is currently used as an immune modulator.
OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.
Ms. Griffin, will be discussing the company’s accomplishments in dynamically effective approaches to combat a variety of chronic, life-threatening diseases. Their novel concepts entail enhancing and refining both the activation and modulation of the body’s natural immune system. The company’s therapies have been demonstrated over time to be highly efficacious and virtually free of side negative effects.
Immune Therapeutics is a specialty pharmaceutical company undergoing a wide range of FDA testing of therapeutic protocols preparatory to the manufacture, commercialization, marketing, and distribution of their patented therapies.
Orlando, Florida and Dublin, Ireland, January 23, 2015 – Immune Therapeutics, Inc. today announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.
ORLANDO, Fla. and DUBLIN, Jan. 21, 2015 /PRNewswire/ — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced that Vincent Butta, a new director appointed to fill a vacancy, and Edward Teraskiewicz, a director elected at the 2014 Annual Meeting of Shareholders, joined the Board on January 13, 2015.
Ms. Noreen Griffin, Chief Executive Officer of Immune Therapeutics, stated, “We are very excited to bring on these new board members as this allows us to begin to make the changes we promised at our annual meeting. We believe these people bring the changes necessary to advance the company to the next level.”